Cinclus Pharma Holding AB (publ), a late‑stage clinical pharmaceutical company developing next‑generation treatments for gastric acid‑related diseases, today announces that its Annual Report for 2025 has been published.
The Annual Report is available at https://cincluspharma.com/investors/financial-reports/. The Swedish version of the report is also available in European Single Electronic Format (ESEF).
“The past year was marked by significant progress for Cinclus Pharma. Our first Phase III study has had a promising start, and we expect to present topline results during the second half of the year. The strategic licensing agreement with Zentiva provides a strong platform for successful commercialization in Europe and lays a solid foundation for expansion into other markets. Following the inclusion of linaprazan glurate on China’s national reimbursement list, our Chinese partner plans to launch the product on the market in 2026. With superior acid control compared to existing treatment options, linaprazan glurate has the potential to meet the substantial medical need among patients suffering from the more severe forms of erosive GERD, which we aim to confirm in the ongoing Phase III study”, says Christer Ahlberg, CEO, Cinclus Pharma.